Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine

OBJECTIVE: Vaccine-associated paralytic poliomyelitis (VAPP) is a rare but serious consequence of the administration of oral polio vaccine (OPV). Intensified OPV administration has reduced wild poliovirus transmission in India but VAPP is becoming a matter of concern. METHODS: We analysed acute flac...

Full description

Bibliographic Details
Main Authors: Kohler Kathryn A., Banerjee Kaushik, Gary Hlady W., Andrus Jon K., Sutter Roland W.
Format: Article
Language:English
Published: The World Health Organization 2002-01-01
Series:Bulletin of the World Health Organization
Subjects:
Online Access:http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862002000300007
_version_ 1797281935041495040
author Kohler Kathryn A.
Banerjee Kaushik
Gary Hlady W.
Andrus Jon K.
Sutter Roland W.
author_facet Kohler Kathryn A.
Banerjee Kaushik
Gary Hlady W.
Andrus Jon K.
Sutter Roland W.
author_sort Kohler Kathryn A.
collection DOAJ
description OBJECTIVE: Vaccine-associated paralytic poliomyelitis (VAPP) is a rare but serious consequence of the administration of oral polio vaccine (OPV). Intensified OPV administration has reduced wild poliovirus transmission in India but VAPP is becoming a matter of concern. METHODS: We analysed acute flaccid paralysis (AFP) surveillance data in order to estimate the VAPP risk in this country. VAPP was defined as occurring in AFP cases with onset of paralysis in 1999, residual weakness 60 days after onset, and isolation of vaccine-related poliovirus. Recipient VAPP cases were a subset with onset of paralysis between 4 and 40 days after receipt of OPV. FINDINGS: A total of 181 AFP cases met the case definition. The following estimates of VAPP risk were made: overall risk, 1 case per 4.1 to 4.6 million OPV doses administered; recipient risk,1 case per 12.2 million; first-dose recipient risk, 1case per 2.8 million; and subsequent-dose recipient risk, 1 case per 13.9 million. CONCLUSION: On the basis of data from a highly sensitive surveillance system the estimated VAPP risk in India is evidently lower than that in other countries, notwithstanding the administration of multiple OPV doses to children in mass immunization campaigns.
first_indexed 2024-03-07T17:04:38Z
format Article
id doaj.art-2e13ff063e324384a6c0f842930be613
institution Directory Open Access Journal
issn 0042-9686
language English
last_indexed 2024-03-07T17:04:38Z
publishDate 2002-01-01
publisher The World Health Organization
record_format Article
series Bulletin of the World Health Organization
spelling doaj.art-2e13ff063e324384a6c0f842930be6132024-03-03T02:43:37ZengThe World Health OrganizationBulletin of the World Health Organization0042-96862002-01-01803210216Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccineKohler Kathryn A.Banerjee KaushikGary Hlady W.Andrus Jon K.Sutter Roland W.OBJECTIVE: Vaccine-associated paralytic poliomyelitis (VAPP) is a rare but serious consequence of the administration of oral polio vaccine (OPV). Intensified OPV administration has reduced wild poliovirus transmission in India but VAPP is becoming a matter of concern. METHODS: We analysed acute flaccid paralysis (AFP) surveillance data in order to estimate the VAPP risk in this country. VAPP was defined as occurring in AFP cases with onset of paralysis in 1999, residual weakness 60 days after onset, and isolation of vaccine-related poliovirus. Recipient VAPP cases were a subset with onset of paralysis between 4 and 40 days after receipt of OPV. FINDINGS: A total of 181 AFP cases met the case definition. The following estimates of VAPP risk were made: overall risk, 1 case per 4.1 to 4.6 million OPV doses administered; recipient risk,1 case per 12.2 million; first-dose recipient risk, 1case per 2.8 million; and subsequent-dose recipient risk, 1 case per 13.9 million. CONCLUSION: On the basis of data from a highly sensitive surveillance system the estimated VAPP risk in India is evidently lower than that in other countries, notwithstanding the administration of multiple OPV doses to children in mass immunization campaigns.http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862002000300007Poliovirus vaccineOral/adverse effectsOral/administration and dosagePoliomyelitis/chemically inducedPoliomyelitis/epidemiologyParalysis/epidemiologyPoliovirus/isolation and purificationRisk assessmentIndia
spellingShingle Kohler Kathryn A.
Banerjee Kaushik
Gary Hlady W.
Andrus Jon K.
Sutter Roland W.
Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
Bulletin of the World Health Organization
Poliovirus vaccine
Oral/adverse effects
Oral/administration and dosage
Poliomyelitis/chemically induced
Poliomyelitis/epidemiology
Paralysis/epidemiology
Poliovirus/isolation and purification
Risk assessment
India
title Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
title_full Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
title_fullStr Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
title_full_unstemmed Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
title_short Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine
title_sort vaccine associated paralytic poliomyelitis in india during 1999 decreased risk despite massive use of oral polio vaccine
topic Poliovirus vaccine
Oral/adverse effects
Oral/administration and dosage
Poliomyelitis/chemically induced
Poliomyelitis/epidemiology
Paralysis/epidemiology
Poliovirus/isolation and purification
Risk assessment
India
url http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862002000300007
work_keys_str_mv AT kohlerkathryna vaccineassociatedparalyticpoliomyelitisinindiaduring1999decreasedriskdespitemassiveuseoforalpoliovaccine
AT banerjeekaushik vaccineassociatedparalyticpoliomyelitisinindiaduring1999decreasedriskdespitemassiveuseoforalpoliovaccine
AT garyhladyw vaccineassociatedparalyticpoliomyelitisinindiaduring1999decreasedriskdespitemassiveuseoforalpoliovaccine
AT andrusjonk vaccineassociatedparalyticpoliomyelitisinindiaduring1999decreasedriskdespitemassiveuseoforalpoliovaccine
AT sutterrolandw vaccineassociatedparalyticpoliomyelitisinindiaduring1999decreasedriskdespitemassiveuseoforalpoliovaccine